Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

IPWatchdog Unleashed

IPWatchdog Unleashed artwork

Law & Politics of Drug Price Controls & Pharma Innovation

Jan 20, 202548 minAudio

Send us Fan Mail This week on IPWatchdog Unleashed we talk about pharmaceutical patents, pharmaceutical patent policy, and innovation. As you may recall, back in 2022, the Inflation Reduction Act passed. And as part of that law, it gave the federal government the opportunity for the first time to “negotiate” drug prices for Medicare. The Biden Administration has viewed this as fantastic. It has allowed them to control drug prices and drug costs for Medicare. The problem is it's not really a negotiation in any fair sense of the word. What happens is the federal government identifies the drugs on which the U.S. government spends the most amount of money, and then they tell the drug companies that you will either take our offer or you will be fined, and the fines are ruinous - in the billions of dollars. So, the IRA negotiation nothing more than a price fixing, price controlling scheme. So why is this an issue for us to consider today if the IRA passed in 2022? Literally on the way out the door, last week Health and Human Services identified 15 more drugs that are now going to be forced into this price fixing “negotiation” scheme. Visit us online at IPWatchdog.com. You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. AI and Super-Fast Followers: Is the Patent Bargain Breaking Down?

    Nov 16, 20261 hrAudio

    Send us Fan Mail This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn, speaks with Emily Johnson, Nicholas Lanzatella, Kwame Mensah, and Corey Salsberg. The panel explores how artificial...

    Credit the people on this episode

  2. Judge Newman’s Challenge: Don’t Just Navigate Patent Law—Change It

    Nov 13, 202611 minAudio

    Send us Fan Mail Uncertainty in patent rights undermines the investment needed to turn scientific breakthroughs into commercial products - but accepting that uncertainty is a choice. In this episode of IPWatchdog...

    Credit the people on this episode

  3. The Art of Patent Litigation: How to Make Your Case Compelling

    Nov 8, 20261 hr 4 minAudio

    Send us Fan Mail Effective patent litigation requires more than command of the law and technology. It demands an advocacy strategy tailored to the audience, the forum, and the business stakes. Recorded at IPWatchdog’s...

    Credit the people on this episode

  4. Is AI Use Putting Intellectual Property at Risk?

    Nov 2, 202655 minAudio

    Send us Fan Mail This week on IPWatchdog Unleashed, generative AI’s accelerating adoption raises a critical question: can organizations move quickly without compromising their intellectual property? Recorded at...

    Credit the people on this episode

  5. USPTO 101: The Risks of Subject Matter Eligibility Declarations

    Oct 26, 202659 minAudio

    Send us Fan Mail This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn, speaks with John Rogitz and Clint Mehall. The conversation examines subject matter eligibility declarations, or...

    Credit the people on this episode